Literature DB >> 22504437

Mycoplasma polysaccharide protects against complement.

Jeffrey R Bolland1, Warren L Simmons, James M Daubenspeck, Kevin Dybvig.   

Abstract

Although they lack a cell wall, mycoplasmas do possess a glycocalyx. The interactions between the glycocalyx, mycoplasmal surface proteins and host complement were explored using the murine pathogen Mycoplasma pulmonis as a model. It was previously shown that the length of the tandem repeat region of the surface lipoprotein Vsa is associated with susceptibility to complement-mediated killing. Cells producing a long Vsa containing about 40 repeats are resistant to complement, whereas strains that produce a short Vsa of five or fewer repeats are susceptible. We show here that the length of the Vsa protein modulates the affinity of the M. pulmonis EPS-I polysaccharide for the mycoplasma cell surface, with more EPS-I being associated with mycoplasmas producing a short Vsa protein. An examination of mutants that lack EPS-I revealed that planktonic mycoplasmas were highly susceptible to complement killing even when the Vsa protein was long, demonstrating that both EPS-I and Vsa length contribute to resistance. In contrast, the mycoplasmas were resistant to complement even in the absence of EPS-I when the cells were encased in a biofilm.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504437      PMCID: PMC3542145          DOI: 10.1099/mic.0.058222-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  21 in total

Review 1.  Adherence of pathogenic mycoplasmas to host cells.

Authors:  S Razin
Journal:  Biosci Rep       Date:  1999-10       Impact factor: 3.840

2.  Variations in the surface proteins and restriction enzyme systems of Mycoplasma pulmonis in the respiratory tract of infected rats.

Authors:  J Gumulak-Smith; A Teachman; A H Tu; J W Simecka; J R Lindsey; K Dybvig
Journal:  Mol Microbiol       Date:  2001-05       Impact factor: 3.501

3.  Murine chronic respiratory disease. Significance as a research complication and experimental production with Mycoplasma pulmonis.

Authors:  J R Lindsey; H J Baker; R G Overcash; G H Cassell; C E Hunt
Journal:  Am J Pathol       Date:  1971-09       Impact factor: 4.307

4.  Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials.

Authors:  Thormika Keo; Jennifer Collins; Pratima Kunwar; Martin J Blaser; Nicole M Iovine
Journal:  Virulence       Date:  2011-01-01       Impact factor: 5.882

5.  Construction and use of derivatives of transposon Tn4001 that function in Mycoplasma pulmonis and Mycoplasma arthritidis.

Authors:  K Dybvig; C T French; L L Voelker
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

6.  Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation.

Authors:  A Alitalo; T Meri; L Rämö; T S Jokiranta; T Heikkilä; I J Seppälä; J Oksi; M Viljanen; S Meri
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 8.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms.

Authors:  D Taylor-Robinson; H U Schorlemmer; P M Furr; A C Allison
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

10.  Sequence analysis of the chromosomal region around and within the V-1-encoding gene of Mycoplasma pulmonis: evidence for DNA inversion as a mechanism for V-1 variation.

Authors:  W L Simmons; C Zuhua; J I Glass; J W Simecka; G H Cassell; H L Watson
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more
  10 in total

1.  O-linked protein glycosylation in Mycoplasma.

Authors:  David S Jordan; James M Daubenspeck; Audra H Laube; Matthew B Renfrow; Kevin Dybvig
Journal:  Mol Microbiol       Date:  2013-10-18       Impact factor: 3.501

2.  Type 1 and type 2 strains of Mycoplasma pneumoniae form different biofilms.

Authors:  Warren L Simmons; James M Daubenspeck; John D Osborne; Mitchell F Balish; Ken B Waites; Kevin Dybvig
Journal:  Microbiology       Date:  2013-02-14       Impact factor: 2.777

3.  Rhamnose biosynthesis in mycoplasmas requires precursor glycans larger than monosaccharide.

Authors:  David S Jordan; James M Daubenspeck; Kevin Dybvig
Journal:  Mol Microbiol       Date:  2013-07-19       Impact factor: 3.501

4.  EPS-I polysaccharide protects Mycoplasma pulmonis from phagocytosis.

Authors:  Brandon M Shaw; James M Daubenspeck; Warren L Simmons; Kevin Dybvig
Journal:  FEMS Microbiol Lett       Date:  2012-11-28       Impact factor: 2.742

5.  In vivo role of capsular polysaccharide in Mycoplasma mycoides.

Authors:  Joerg Jores; Elise Schieck; Anne Liljander; Flavio Sacchini; Horst Posthaus; Carole Lartigue; Alain Blanchard; Fabien Labroussaa; Sanjay Vashee
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

6.  Toll-Like Receptor 2 (TLR2) and TLR4 Mediate the IgA Immune Response Induced by Mycoplasma hyopneumoniae.

Authors:  Xia Li; Yun-Ke Zhang; Bao Yin; Jing-Bo Liang; Fei Jiang; Wen-Xue Wu
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

Review 7.  Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors.

Authors:  Chen Yiwen; Wu Yueyue; Qin Lianmei; Zhu Cuiming; You Xiaoxing
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 8.  The Mycoplasma spp. 'Releasome': A New Concept for a Long-Known Phenomenon.

Authors:  Patrice Gaurivaud; Florence Tardy
Journal:  Front Microbiol       Date:  2022-04-15       Impact factor: 5.640

9.  Antibodies Specific to Membrane Proteins Are Effective in Complement-Mediated Killing of Mycoplasma bovis.

Authors:  Yun-Ke Zhang; Xia Li; Hao-Ran Zhao; Fei Jiang; Zhan-Hui Wang; Wen-Xue Wu
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

10.  Mycoplasma hyopneumoniae evades complement activation by binding to factor H via elongation factor thermo unstable (EF-Tu).

Authors:  Yanfei Yu; Jia Wang; Rui Han; Li Wang; Lei Zhang; Amy Yimin Zhang; Jiuqing Xin; Shaoli Li; Yanhua Zeng; Guoqing Shao; Zhixin Feng; Qiyan Xiong
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.